Minoo Bagheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minoo Bagheri has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Jane F. Ferguson
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
6 shared publications - Jonathan D. Mosley
Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
6 shared publications - Kurosh Djafarian
Tehran University of Medical Sciences
3 shared publications - Mingjian Shi
Department of Medical and Clinical Psychology Uniformed Services University of the Health Sciences Bethesda Maryland USA
3 shared publications - Mir Saeed Yekaninejad
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Olaf Uhl
Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children's Hospital, LMU-Ludwig-Maximilians-Universität München, University of Munich Medical Centre, Campus Innenstadt, Lindwurmstr. 4, 80337, Munich, Germany
3 shared publications
Latest Publications
- Open Access
Association of cognitive impairment with statin use in coronary artery disease across APO (ε) genotypes in AllofUS
STRUCTERED BACKGROUND: Coronary artery disease (CAD) and Impaired Cognitive (IC) disease share sociodemographic, genetic, and clinical factors, but the association of IC with statin use in CAD remains unclear. OBJECTIVES: To determine the association between IC and statin use in CAD based on APO (ε) genotype, sex, and lipid levels. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective study of AllofUS (AoU) participants with CAD (age≥60 yrs) enrolled from 2017 to 2023. We defined CAD as having a history of angina/myocardial infarction/chronic ischemic heart disease or having percutaneous coronary intervention/CABG, and IC defined as mild cognitive impairment or all-cause dementia, using ICD/SNOMED codes. MEASURES: We assessed the association between IC and statin use using logistic regression analysis, while adjusting for clinical factors, sociodemographics, and APO (ε) genotypes before and after propensity score matching. We further performed stratified analysis by sex, and APO (ε) genotypes. We finally assessed the association between IC and statin users, based magnitude on the change in lipid levels before CAD and after IC (TC-Total cholesterol, LDL – low density lipoprotein, HDL-High Density Lipoprotein). Significance was defined at p < 0.05. RESULTS: The cohort included 22,089 participants with CAD and 1343 with IC. Thirty-nine percent of participants were females, 77% were European, 13% were African American, and 9% were of Admixed American ancestry. The proportion of IC was higher ( 6.8% vs 3.5%, p ) in statin users (n=17,191) vs non-statin users (n=4,898). IC was significantly associated with statin use ( OR:1.70;1.40-2.10, p = 4.9e-7 ) after adjustment for clinical factors, sociodemographics, and APO (ε) genotypes. After propensity-score matching between IC and CAD, we observed an association between IC and statin use ( OR:1.55;1.24-1.94, p =1e-4 ). In stratified analysis, the association between IC and statin use was strongest in the APO ε3/ε3 group ( OR:2.04;1.53-2.75, p = 1e-6 ), and in females ( OR:2.20;1.60-3.06, p = 2.e-6 ) compared to males (OR:1.43;1.10-1.90, p = 0.01). We finally observed an increased magnitude of association between IC and statin users having higher HDL increase ( > 10 mg/dl: OR:1.95;1.44-2.66, p=1e-5 ) as compared to statin users with lesser HDL increase ( ≤ 10mg/dl: OR:1.61;1.22-2.15, p=8e-4 ). CONCLUSION: In the AllofUS cohort, IC was significantly associated with statin use in CAD participants. We observed the strongest association in the APO ε3ε3 group, among females, and with a greater increase in HDL levels in statin users. Key Message: What is already known on this topic: Coronary artery disease (CAD) and Impaired Cognitive (IC) disease, i.e., mild cognitive impairment or all-cause dementia, share genetic, sociodemographic, and clinical risk factors but the association of IC with statin use in CAD remains unclear. What this study adds: We observed an association between IC and statin use in CAD participants after adjusting for sociodemographics, clinical factors, and APO (ε) genotypes. The association persisted after propensity score matching for sociodemographics, clinical factors, and APO (ε) genotypes. Further, when CAD participants were stratified across APO (ε) groups and by sex, we observed strongest magnitude of association between IC and statin use in the APO ε3ε3 compared to other APO (ε) genotypes, and in females compared to males. Among CAD participants with documented baseline and latest lipids (total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL)), IC was associated with statin use regardless of baseline lipid levels or latest lipid levels. While we did not observe any change in association between IC and statin use, based on the magnitude of decrease in TC and LDL levels, we observed a higher magnitude of association between IC and statin use, with a greater increase in HDL levels. How this study might affect research, practice or policy: Our observations highlight the association of IC and statin use in CAD and the role of APO (ε) genotype evaluation, and serial lipid level assessments for evaluating for statin associated IC in CAD.
Open AccessAssociation of cognitive impairment with statin use in coronary artery disease across APO (ε) genotypes in AllofUS
STRUCTERED BACKGROUND: Coronary artery disease (CAD) and Impaired Cognitive (IC) disease share sociodemographic, genetic, and clinical factors, but the association of IC with statin use in CAD remains unclear. OBJECTIVES: To determine the association between IC and statin use in CAD based on APO (ε) genotype, sex, and lipid levels. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective study of AllofUS (AoU) participants with CAD (age≥60 yrs) enrolled from 2017 to 2023. We defined CAD as having a history of angina/myocardial infarction/chronic ischemic heart disease or having percutaneous coronary intervention/CABG, and IC defined as mild cognitive impairment or all-cause dementia, using ICD/SNOMED codes. MEASURES: We assessed the association between IC and statin use using logistic regression analysis, while adjusting for clinical factors, sociodemographics, and APO (ε) genotypes before and after propensity score matching. We further performed stratified analysis by sex, and APO (ε) genotypes. We finally assessed the association between IC and statin users, based magnitude on the change in lipid levels before CAD and after IC (TC-Total cholesterol, LDL – low density lipoprotein, HDL-High Density Lipoprotein). Significance was defined at p < 0.05. RESULTS: The cohort included 22,089 participants with CAD and 1343 with IC. Thirty-nine percent of participants were females, 77% were European, 13% were African American, and 9% were of Admixed American ancestry. The proportion of IC was higher ( 6.8% vs 3.5%, p ) in statin users (n=17,191) vs non-statin users (n=4,898). IC was significantly associated with statin use ( OR:1.70;1.40-2.10, p = 4.9e-7 ) after adjustment for clinical factors, sociodemographics, and APO (ε) genotypes. After propensity-score matching between IC and CAD, we observed an association between IC and statin use ( OR:1.55;1.24-1.94, p =1e-4 ). In stratified analysis, the association between IC and statin use was strongest in the APO ε3/ε3 group ( OR:2.04;1.53-2.75, p = 1e-6 ), and in females ( OR:2.20;1.60-3.06, p = 2.e-6 ) compared to males (OR:1.43;1.10-1.90, p = 0.01). We finally observed an increased magnitude of association between IC and statin users having higher HDL increase ( > 10 mg/dl: OR:1.95;1.44-2.66, p=1e-5 ) as compared to statin users with lesser HDL increase ( ≤ 10mg/dl: OR:1.61;1.22-2.15, p=8e-4 ). CONCLUSION: In the AllofUS cohort, IC was significantly associated with statin use in CAD participants. We observed the strongest association in the APO ε3ε3 group, among females, and with a greater increase in HDL levels in statin users. Key Message: What is already known on this topic: Coronary artery disease (CAD) and Impaired Cognitive (IC) disease, i.e., mild cognitive impairment or all-cause dementia, share genetic, sociodemographic, and clinical risk factors but the association of IC with statin use in CAD remains unclear. What this study adds: We observed an association between IC and statin use in CAD participants after adjusting for sociodemographics, clinical factors, and APO (ε) genotypes. The association persisted after propensity score matching for sociodemographics, clinical factors, and APO (ε) genotypes. Further, when CAD participants were stratified across APO (ε) groups and by sex, we observed strongest magnitude of association between IC and statin use in the APO ε3ε3 compared to other APO (ε) genotypes, and in females compared to males. Among CAD participants with documented baseline and latest lipids (total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL)), IC was associated with statin use regardless of baseline lipid levels or latest lipid levels. While we did not observe any change in association between IC and statin use, based on the magnitude of decrease in TC and LDL levels, we observed a higher magnitude of association between IC and statin use, with a greater increase in HDL levels. How this study might affect research, practice or policy: Our observations highlight the association of IC and statin use in CAD and the role of APO (ε) genotype evaluation, and serial lipid level assessments for evaluating for statin associated IC in CAD.
- 11 October 2025
- Published by Springer Nature
- p. 359-371
Unraveling the Impact and Benefits of Chrononutrition and Circadian Rhythms on Health
- 11 October 2025
- Published by Springer Nature
- p. 359-371
Unraveling the Impact and Benefits of Chrononutrition and Circadian Rhythms on Health
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (1) , e010557
Identification of Clinical Drivers of Left Atrial Enlargement Through Genomics of Left Atrial Size
BACKGROUND: Greater left atrial size is associated with a higher incidence of cardiovascular disease and mortality, but the full spectrum of diagnoses associated with left atrial enlargement in sex-stratified clinical populations is not well known. Our study sought to identify genetic risk mechanisms affecting left atrial diameter (LAD) in a clinical cohort. METHODS: Using Vanderbilt deidentified electronic health record, we studied 6163 females and 5993 males of European ancestry who had at least 1 LAD measure and available genotyping. A sex-stratified polygenic score was constructed for LAD variation and tested for association against 1680 International Classification of Diseases code–based phenotypes. Two-sample univariable and multivariable Mendelian randomization approaches were used to assess etiologic relationships between candidate associations and LAD. RESULTS: A phenome-wide association study identified 25 International Classification of Diseases code–based diagnoses in females and 11 in males associated with a polygenic score of LAD (false discovery rate q<0.01), 5 of which were further evaluated by Mendelian randomization (waist circumference [WC], atrial fibrillation, heart failure, systolic blood pressure, and coronary artery disease). Sex-stratified differences in the genetic associations between risk factors and a polygenic score for LAD were observed (WC for females; heart failure, systolic blood pressure, atrial fibrillation, and WC for males). By multivariable Mendelian randomization, higher WC remained significantly associated with larger LAD in females, whereas coronary artery disease, WC, and atrial fibrillation remained significantly associated with larger LAD in males. CONCLUSIONS: In a clinical population, we identified, by genomic approaches, potential etiologic risk factors for larger LAD. Further studies are needed to confirm the extent to which these risk factors may be modified to prevent or reverse adverse left atrial remodeling and the extent to which sex modifies these risk factors.
- 1 January 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (1) , e010557
Identification of Clinical Drivers of Left Atrial Enlargement Through Genomics of Left Atrial Size
BACKGROUND: Greater left atrial size is associated with a higher incidence of cardiovascular disease and mortality, but the full spectrum of diagnoses associated with left atrial enlargement in sex-stratified clinical populations is not well known. Our study sought to identify genetic risk mechanisms affecting left atrial diameter (LAD) in a clinical cohort. METHODS: Using Vanderbilt deidentified electronic health record, we studied 6163 females and 5993 males of European ancestry who had at least 1 LAD measure and available genotyping. A sex-stratified polygenic score was constructed for LAD variation and tested for association against 1680 International Classification of Diseases code–based phenotypes. Two-sample univariable and multivariable Mendelian randomization approaches were used to assess etiologic relationships between candidate associations and LAD. RESULTS: A phenome-wide association study identified 25 International Classification of Diseases code–based diagnoses in females and 11 in males associated with a polygenic score of LAD (false discovery rate q<0.01), 5 of which were further evaluated by Mendelian randomization (waist circumference [WC], atrial fibrillation, heart failure, systolic blood pressure, and coronary artery disease). Sex-stratified differences in the genetic associations between risk factors and a polygenic score for LAD were observed (WC for females; heart failure, systolic blood pressure, atrial fibrillation, and WC for males). By multivariable Mendelian randomization, higher WC remained significantly associated with larger LAD in females, whereas coronary artery disease, WC, and atrial fibrillation remained significantly associated with larger LAD in males. CONCLUSIONS: In a clinical population, we identified, by genomic approaches, potential etiologic risk factors for larger LAD. Further studies are needed to confirm the extent to which these risk factors may be modified to prevent or reverse adverse left atrial remodeling and the extent to which sex modifies these risk factors.
- 13 December 2023
- Published by Springer Nature
- p. 257-273
Systematic Review and Meta-Analysis: Evidence-Based Decision-Making in Public Health
- 13 December 2023
- Published by Springer Nature
- p. 257-273
Systematic Review and Meta-Analysis: Evidence-Based Decision-Making in Public Health
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e029190
Genetics of Pulmonary Pressure and Right Ventricle Stress Identify Diabetes as a Causal Risk Factor
Background: Epidemiologic studies have identified risk factors associated with pulmonary hypertension and right heart failure, but causative drivers of pulmonary hypertension and right heart adaptation are not well known. We sought to leverage unbiased genetic approaches to determine clinical conditions that share genetic architecture with pulmonary pressure and right ventricular dysfunction. Methods and Results: We leveraged Vanderbilt University's deidentified electronic health records and DNA biobank to identify 14 861 subjects of European ancestry who underwent at least 1 echocardiogram with available estimates of pulmonary pressure and right ventricular function. Analyses of the study were performed between 2020 and 2022. The final analytical sample included 14 861 participants (mean [SD] age, 63 [15] years and mean [SD] body mass index, 29 [7] kg/m 2 ). An unbiased phenome‐wide association study identified diabetes as the most statistically significant clinical International Classifications of Diseases , Ninth Revision ( ICD‐9 ) code associated with polygenic risk for increased pulmonary pressure. We validated this finding further by finding significant associations between genetic risk for diabetes and a related condition, obesity, with pulmonary pressure estimate. We then used 2‐sample univariable Mendelian randomization and multivariable Mendelian randomization to show that diabetes, but not obesity, was independently associated with genetic risk for increased pulmonary pressure and decreased right ventricle load stress. Conclusions: Our findings show that genetic risk for diabetes is the only significant independent causative driver of genetic risk for increased pulmonary pressure and decreased right ventricle load stress. These findings suggest that therapies targeting genetic risk for diabetes may also potentially be beneficial in treating pulmonary hypertension and right heart dysfunction.
- 1 August 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (15) , e029190
Open AccessGenetics of Pulmonary Pressure and Right Ventricle Stress Identify Diabetes as a Causal Risk Factor
Background: Epidemiologic studies have identified risk factors associated with pulmonary hypertension and right heart failure, but causative drivers of pulmonary hypertension and right heart adaptation are not well known. We sought to leverage unbiased genetic approaches to determine clinical conditions that share genetic architecture with pulmonary pressure and right ventricular dysfunction. Methods and Results: We leveraged Vanderbilt University's deidentified electronic health records and DNA biobank to identify 14 861 subjects of European ancestry who underwent at least 1 echocardiogram with available estimates of pulmonary pressure and right ventricular function. Analyses of the study were performed between 2020 and 2022. The final analytical sample included 14 861 participants (mean [SD] age, 63 [15] years and mean [SD] body mass index, 29 [7] kg/m 2 ). An unbiased phenome‐wide association study identified diabetes as the most statistically significant clinical International Classifications of Diseases , Ninth Revision ( ICD‐9 ) code associated with polygenic risk for increased pulmonary pressure. We validated this finding further by finding significant associations between genetic risk for diabetes and a related condition, obesity, with pulmonary pressure estimate. We then used 2‐sample univariable Mendelian randomization and multivariable Mendelian randomization to show that diabetes, but not obesity, was independently associated with genetic risk for increased pulmonary pressure and decreased right ventricle load stress. Conclusions: Our findings show that genetic risk for diabetes is the only significant independent causative driver of genetic risk for increased pulmonary pressure and decreased right ventricle load stress. These findings suggest that therapies targeting genetic risk for diabetes may also potentially be beneficial in treating pulmonary hypertension and right heart dysfunction.
- Open Access
Relationship between branched chain amino acids and type 2 diabetes: a bidirectional Mendelian Randomization study
Background: Human genetic studies suggest that the branched chain amino acids (BCAA) valine, leucine and isoleucine have a causal association with type 2 diabetes. However, inferences are based on analyses of a limited number of genetic loci associated with BCAAs. Whether these conclusions are supported when using instrumental variables for BCAAs that capture a broad set of genetic mechanisms is not known. Methods: We constructed and validated instrumental variables for each BCAA using large well-powered datasets and tested their association with type 2 diabetes using the two-sample inverse variance weighted (IWV) Mendelian randomization (MR) approach. Sensitivity analyses were performed to ensure the accuracy of the findings. Instrumental variables for type 2 diabetes, fasting insulin and body mass index (BMI) were also tested for associations with BCAA levels. Results: There were no significant associations with diabetes for valine (beta=0.17 change in log-odds per standard deviation change in valine, [95% CI, −0.28 - 0.62], p=0.45), leucine (beta=0.19 [−0.30 - 0.68] p=0.45) or isoleucine (beta=0.02 [−0.54 - 0.59], p=0.94). In contrast, type 2 diabetes was associated with each BCAA (valine: beta=0.08 per standard deviation change in levels per log-odds change in type 2 diabetes, [0.05 - 0.10], p=1.8×10 −9 ), (leucine: beta= 0.06 [0.04 - 0.09], p=4.5×10 −8 ) and isoleucine (beta= 0.06 [0.04 - 0.08], p=2.8×10 −8 ). The type 2 diabetes associations were replicated in an independent population, but not in a second population where type 2 diabetes cases were removed, highlighting the consistency and specificity of the association. Similar positive associations were seen for fasting insulin and BMI with the BCAAs. In multivariable MR analyses, type 2 diabetes and fasting insulin had consistent independent associations with each BCAA. Conclusions: These data suggest that the BCAAs are not mediators of type 2 diabetes risk but are biomarkers of diabetes and higher insulin.
Open AccessRelationship between branched chain amino acids and type 2 diabetes: a bidirectional Mendelian Randomization study
Background: Human genetic studies suggest that the branched chain amino acids (BCAA) valine, leucine and isoleucine have a causal association with type 2 diabetes. However, inferences are based on analyses of a limited number of genetic loci associated with BCAAs. Whether these conclusions are supported when using instrumental variables for BCAAs that capture a broad set of genetic mechanisms is not known. Methods: We constructed and validated instrumental variables for each BCAA using large well-powered datasets and tested their association with type 2 diabetes using the two-sample inverse variance weighted (IWV) Mendelian randomization (MR) approach. Sensitivity analyses were performed to ensure the accuracy of the findings. Instrumental variables for type 2 diabetes, fasting insulin and body mass index (BMI) were also tested for associations with BCAA levels. Results: There were no significant associations with diabetes for valine (beta=0.17 change in log-odds per standard deviation change in valine, [95% CI, −0.28 - 0.62], p=0.45), leucine (beta=0.19 [−0.30 - 0.68] p=0.45) or isoleucine (beta=0.02 [−0.54 - 0.59], p=0.94). In contrast, type 2 diabetes was associated with each BCAA (valine: beta=0.08 per standard deviation change in levels per log-odds change in type 2 diabetes, [0.05 - 0.10], p=1.8×10 −9 ), (leucine: beta= 0.06 [0.04 - 0.09], p=4.5×10 −8 ) and isoleucine (beta= 0.06 [0.04 - 0.08], p=2.8×10 −8 ). The type 2 diabetes associations were replicated in an independent population, but not in a second population where type 2 diabetes cases were removed, highlighting the consistency and specificity of the association. Similar positive associations were seen for fasting insulin and BMI with the BCAAs. In multivariable MR analyses, type 2 diabetes and fasting insulin had consistent independent associations with each BCAA. Conclusions: These data suggest that the BCAAs are not mediators of type 2 diabetes risk but are biomarkers of diabetes and higher insulin.
- Open Access
- 30 January 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (3) , 406-409
White blood cell ranges and frequency of neutropenia by Duffy genotype status
- 30 January 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (3) , 406-409
Open AccessWhite blood cell ranges and frequency of neutropenia by Duffy genotype status
- Open Access
- 23 August 2022
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 20 (8) , e3001758
Individuality and ethnicity eclipse a short-term dietary intervention in shaping microbiomes and viromes
Many diseases linked with ethnic health disparities associate with changes in microbial communities in the United States, but the causes and persistence of ethnicity-associated microbiome variation are not understood. For instance, microbiome studies that strictly control for diet across ethnically diverse populations are lacking. Here, we performed multiomic profiling over a 9-day period that included a 4-day controlled vegetarian diet intervention in a defined geographic location across 36 healthy Black and White females of similar age, weight, habitual diets, and health status. We demonstrate that individuality and ethnicity account for roughly 70% to 88% and 2% to 10% of taxonomic variation, respectively, eclipsing the effects a short-term diet intervention in shaping gut and oral microbiomes and gut viromes. Persistent variation between ethnicities occurs for microbial and viral taxa and various metagenomic functions, including several gut KEGG orthologs, oral carbohydrate active enzyme categories, cluster of orthologous groups of proteins, and antibiotic-resistant gene categories. In contrast to the gut and oral microbiome data, the urine and plasma metabolites tend to decouple from ethnicity and more strongly associate with diet. These longitudinal, multiomic profiles paired with a dietary intervention illuminate previously unrecognized associations of ethnicity with metagenomic and viromic features across body sites and cohorts within a single geographic location, highlighting the importance of accounting for human microbiome variation in research, health determinants, and eventual therapies. Trial Registration: ClinicalTrials.gov ClinicalTrials.gov Identifier: NCT03314194.
- 23 August 2022
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 20 (8) , e3001758
Open AccessIndividuality and ethnicity eclipse a short-term dietary intervention in shaping microbiomes and viromes
Many diseases linked with ethnic health disparities associate with changes in microbial communities in the United States, but the causes and persistence of ethnicity-associated microbiome variation are not understood. For instance, microbiome studies that strictly control for diet across ethnically diverse populations are lacking. Here, we performed multiomic profiling over a 9-day period that included a 4-day controlled vegetarian diet intervention in a defined geographic location across 36 healthy Black and White females of similar age, weight, habitual diets, and health status. We demonstrate that individuality and ethnicity account for roughly 70% to 88% and 2% to 10% of taxonomic variation, respectively, eclipsing the effects a short-term diet intervention in shaping gut and oral microbiomes and gut viromes. Persistent variation between ethnicities occurs for microbial and viral taxa and various metagenomic functions, including several gut KEGG orthologs, oral carbohydrate active enzyme categories, cluster of orthologous groups of proteins, and antibiotic-resistant gene categories. In contrast to the gut and oral microbiome data, the urine and plasma metabolites tend to decouple from ethnicity and more strongly associate with diet. These longitudinal, multiomic profiles paired with a dietary intervention illuminate previously unrecognized associations of ethnicity with metagenomic and viromic features across body sites and cohorts within a single geographic location, highlighting the importance of accounting for human microbiome variation in research, health determinants, and eventual therapies. Trial Registration: ClinicalTrials.gov ClinicalTrials.gov Identifier: NCT03314194.
- 31 August 2021
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 14 (5) , e003341
Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults
Background: Polygenic risk scores (PRS) may enhance risk stratification for coronary heart disease among young adults. Whether a coronary heart disease PRS improves prediction beyond modifiable risk factors in this population is not known. Methods: Genotyped adults aged 18 to 35 years were selected from the CARDIA study (Coronary Artery Risk Development in Young Adults; n=1132) and FOS (Framingham Offspring Study; n=663). Systolic blood pressure, total and HDL (high-density lipoprotein) cholesterol, triglycerides, smoking, and waist circumference or body mass index were measured at the visit 1 exam of each study, and coronary artery calcium, a measure of coronary atherosclerosis, was assessed at year 15 (CARDIA) or year 30 (FOS). A previously validated PRS for coronary heart disease was computed for each subject. The C statistic and integrated discrimination improvement were used to compare improvements in prediction of elevated coronary artery calcium between models containing the PRS, risk factors, or both. Results: There were 62 (5%) and 93 (14%) participants with a coronary artery calcium score >20 (CARDIA) and >300 (FOS), respectively. At these thresholds, the C statistic changes of adding the PRS to a risk factor–based model were 0.015 (0.004–0.028) and 0.020 (0.001–0.039) in CARDIA and FOS, respectively. When adding risk factors to a PRS-based model, the respective changes were 0.070 (0.033–0.109) and 0.051 (0.017–0.079). The integrated discrimination improvement, when adding the PRS to a risk factor model, was 0.027 (−0.006 to 0.054) in CARDIA and 0.039 (0.0005–0.072) in FOS. Conclusions: Among young adults, a PRS improved model discrimination for coronary atherosclerosis, but improvements were smaller than those associated with modifiable risk factors.
- 31 August 2021
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 14 (5) , e003341
Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults
Background: Polygenic risk scores (PRS) may enhance risk stratification for coronary heart disease among young adults. Whether a coronary heart disease PRS improves prediction beyond modifiable risk factors in this population is not known. Methods: Genotyped adults aged 18 to 35 years were selected from the CARDIA study (Coronary Artery Risk Development in Young Adults; n=1132) and FOS (Framingham Offspring Study; n=663). Systolic blood pressure, total and HDL (high-density lipoprotein) cholesterol, triglycerides, smoking, and waist circumference or body mass index were measured at the visit 1 exam of each study, and coronary artery calcium, a measure of coronary atherosclerosis, was assessed at year 15 (CARDIA) or year 30 (FOS). A previously validated PRS for coronary heart disease was computed for each subject. The C statistic and integrated discrimination improvement were used to compare improvements in prediction of elevated coronary artery calcium between models containing the PRS, risk factors, or both. Results: There were 62 (5%) and 93 (14%) participants with a coronary artery calcium score >20 (CARDIA) and >300 (FOS), respectively. At these thresholds, the C statistic changes of adding the PRS to a risk factor–based model were 0.015 (0.004–0.028) and 0.020 (0.001–0.039) in CARDIA and FOS, respectively. When adding risk factors to a PRS-based model, the respective changes were 0.070 (0.033–0.109) and 0.051 (0.017–0.079). The integrated discrimination improvement, when adding the PRS to a risk factor model, was 0.027 (−0.006 to 0.054) in CARDIA and 0.039 (0.0005–0.072) in FOS. Conclusions: Among young adults, a PRS improved model discrimination for coronary atherosclerosis, but improvements were smaller than those associated with modifiable risk factors.
- 31 May 2021
- Published by Springer Nature in European Journal of Nutrition
- Vol. 60 (8) , 4413-4427
A metabolome and microbiome wide association study of healthy eating index points to the mechanisms linking dietary pattern and metabolic status
Background Healthy eating index (HEI), a measure of diet quality, associates with metabolic health outcomes; however, the molecular basis is unclear. We conducted a multi-omic study to examine whether HEI associates with the circulatory and gut metabolome and investigated the gut microbiome–HEI interaction on circulating and gut metabolites. Methods Through a cross-sectional study, we evaluated diet quality in healthy individuals [the ABO Glycoproteomics in Platelets and Endothelial Cells (ABO) Study, n = 73], metabolites (measured at Metabolon Inc.) in plasma (n = 800) and gut (n = 767) and the gut microbiome at enterotype and microbial taxa (n = 296) levels. Pathway analysis was conducted using Metaboanalyst 4.0. We performed multi-variable linear regression to explore both the HEI-metabolites and HEI-microbiome associations and how metabolites were affected by the HEI–microbiome interaction. In the Fish oils and Adipose Inflammation Reduction (FAIR) Study (n = 25), analyses on HEI and plasma metabolites were replicated. Estimates of findings from both studies were pooled in random-effects meta-analysis. Results The HEI-2015 was associated with 74 plasma and 73 gut metabolites (mostly lipids) and with 47 metabolites in the meta-analysis of the ABO and FAIR Studies. Compared to Enterotype-1 participants, those with Enterotype-2 had higher diet quality (p = 0.01). We also identified 9 microbial genera associated with HEI, and 35 plasma and 40 gut metabolites linked to the HEI–gut microbiome interaction. Pathways involved in the metabolism of polar lipids, amino acids and caffeine strongly associated with diet quality. However, the HEI–microbiome interaction not only influenced the pathways involved in the metabolism of branch-chain amino acids, it also affected upstream pathways including nucleotide metabolism and amino acids biosynthesis. Conclusions Our multi-omic analysis demonstrated that changes in metabolism, measured by either circulatory/gut metabolites or metabolic pathways, are influenced by not only diet quality but also gut microbiome alterations shaped by the quality of diet consumed. Future work is needed to explore the causality in the interplay between HEI and gut-microbiome composition in metabolism.
- 31 May 2021
- Published by Springer Nature in European Journal of Nutrition
- Vol. 60 (8) , 4413-4427
A metabolome and microbiome wide association study of healthy eating index points to the mechanisms linking dietary pattern and metabolic status
Background Healthy eating index (HEI), a measure of diet quality, associates with metabolic health outcomes; however, the molecular basis is unclear. We conducted a multi-omic study to examine whether HEI associates with the circulatory and gut metabolome and investigated the gut microbiome–HEI interaction on circulating and gut metabolites. Methods Through a cross-sectional study, we evaluated diet quality in healthy individuals [the ABO Glycoproteomics in Platelets and Endothelial Cells (ABO) Study, n = 73], metabolites (measured at Metabolon Inc.) in plasma (n = 800) and gut (n = 767) and the gut microbiome at enterotype and microbial taxa (n = 296) levels. Pathway analysis was conducted using Metaboanalyst 4.0. We performed multi-variable linear regression to explore both the HEI-metabolites and HEI-microbiome associations and how metabolites were affected by the HEI–microbiome interaction. In the Fish oils and Adipose Inflammation Reduction (FAIR) Study (n = 25), analyses on HEI and plasma metabolites were replicated. Estimates of findings from both studies were pooled in random-effects meta-analysis. Results The HEI-2015 was associated with 74 plasma and 73 gut metabolites (mostly lipids) and with 47 metabolites in the meta-analysis of the ABO and FAIR Studies. Compared to Enterotype-1 participants, those with Enterotype-2 had higher diet quality (p = 0.01). We also identified 9 microbial genera associated with HEI, and 35 plasma and 40 gut metabolites linked to the HEI–gut microbiome interaction. Pathways involved in the metabolism of polar lipids, amino acids and caffeine strongly associated with diet quality. However, the HEI–microbiome interaction not only influenced the pathways involved in the metabolism of branch-chain amino acids, it also affected upstream pathways including nucleotide metabolism and amino acids biosynthesis. Conclusions Our multi-omic analysis demonstrated that changes in metabolism, measured by either circulatory/gut metabolites or metabolic pathways, are influenced by not only diet quality but also gut microbiome alterations shaped by the quality of diet consumed. Future work is needed to explore the causality in the interplay between HEI and gut-microbiome composition in metabolism.